Bianca Hemmingsen: key facts
- Kind of voice
- Academic
- Role
- Technical Lead – Diabetes, Department of Noncommunicable Diseases and Mental Health, World Health Organization (WHO)
- Quoted on
- Diabetes
- Tracked press citations
- 2
- Most recently quoted
- 30 Sept 2026
“Across all life stages, access to essential diabetes medicines, including insulin, and to technologies and ongoing support is critical.”
What Bianca Hemmingsen has said
“WHO Prequalification does not re-evaluate whether semaglutide works or is safe – that has already been established through clinical trials, subsequent approvals by stringent national regulatory authorities and confirmed by its inclusion on the WHO Essential Medicines List. What WHO Prequalification assesses is whether a specific [generic] manufacturer can produce semaglutide at the required quality standard.”
technical lead for diabetes at WHO · Diabetes · 30 Sept 2026 · WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drug ↗
Where Bianca Hemmingsen has been quoted
- Diabetes across Life Stages: A Growing Global Challengeun.org · 30 Sept 2026
- WHO Moves to Expand Access to Fast-Acting Insulin and Semaglutide, the Popular Diabetes and Obesity Control Drughealthpolicy-watch.news · 30 Sept 2026
Related media coverage
Recent UK press coverage of their topics — not necessarily citing them directly.
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.